{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:54:07Z","timestamp":1789430047177,"version":"build-2803163510"},"reference-count":30,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T00:00:00Z","timestamp":1585612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011665","name":"Deanship of Scientific Research, King Saud University","doi-asserted-by":"publisher","award":["RG\u20131435-072."],"award-info":[{"award-number":["RG\u20131435-072."]}],"id":[{"id":"10.13039\/501100011665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Baricitinib, is a selective and reversible Janus kinase inhibitor, is commonly used to treat adult patients with moderately to severely active rheumatoid arthritis (RA). A fast, reproducible and sensitive method of liquid chromatography-tandem mass spectrometry (LC-MS\/MS) for the quantification of baricitinib in rat plasma has been developed. Irbersartan was used as the internal standard (IS). Baracitinib and IS were extracted from plasma by liquid\u2013liquid extraction using a mixture of n-hexane and dichloromethane (1:1) as extracting agent. Chromatographic separation was performed using Acquity UPLC HILIC BEH 1.7 \u00b5m 2.1 \u00d7 50 mm column with the mobile phase consisting of 0.1% formic acid in acetonitrile and 20 mM ammonium acetate (pH 3) (97:3). The electrospray ionization in the positive-mode was used for sample ionization in the multiple reaction monitoring mode. Baricitinib and the IS were quantified using precursor-to-production transitions of m\/z 372.15 &gt; 251.24 and 429.69 &gt; 207.35 for baricitinib and IS, respectively. The method was validated according to the recent FDA and EMA guidelines for bioanalytical method validation. The lower limit of quantification was 0.2 ng\/mL, whereas the intra-day and inter-day accuracies of quality control (QCs) samples were ranged between 85.31% to 89.97% and 87.50% to 88.33%, respectively. Linearity, recovery, precision, and stability parameters were found to be within the acceptable range. The method was applied successfully applied in pilot pharmacokinetic studies.<\/jats:p>","DOI":"10.3390\/molecules25071600","type":"journal-article","created":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T05:55:16Z","timestamp":1585893316000},"page":"1600","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A Hydrophilic Interaction Liquid Chromatography\u2013Tandem Mass Spectrometry Quantitative Method for Determination of Baricitinib in Plasma, and Its Application in a Pharmacokinetic Study in Rats"],"prefix":"10.3390","volume":"25","author":[{"given":"Essam","family":"Ezzeldin","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry and Drug Bioavailability Unit, Central Laboratory, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia"},{"name":"National Organization for Drug Control and Research, Cairo 12611, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffar","family":"Iqbal","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry and Drug Bioavailability Unit, Central Laboratory, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousif A.","family":"Asiri","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Department, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azza A","family":"Ali","sequence":"additional","affiliation":[{"name":"Pharmacology and Toxicology Department, Faculty of Pharmacy (Girls) Al-Azhar University, Cairo 11754, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prawez","family":"Alam","sequence":"additional","affiliation":[{"name":"Pharmacognosy Department, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toqa","family":"El-Nahhas","sequence":"additional","affiliation":[{"name":"Pharmacology and Toxicology Department, Faculty of Pharmacy (Girls) Al-Azhar University, Cairo 11754, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,3,31]]},"reference":[{"key":"ref_1","unstructured":"Goldman, M.B., and Hatch, M.C. (2000). 53\u2014Rheumatoid Arthritis. Women and Health, Academic Press."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.17305\/bjbms.2010.2680","article-title":"Ocular manifestation of rheumatoid arthritis-different forms and frequency","volume":"10","author":"Zlatanovic","year":"2010","journal-title":"Bosn. J. Basic Med. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Ljung, L., Ueda, P., Liao, K.P., Greenberg, J.D., Etzel, C.J., Solomon, D.H., and Askling, J. (2018). Performance of the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis in a geographically distant National Register-based cohort: An external validation. RMD Open, 4.","DOI":"10.1136\/rmdopen-2018-000771"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Bartoloni, E., Alunno, A., Valentini, V., Luccioli, F., Valentini, E., La Paglia, G.M.C., Leone, M.C., Cafaro, G., Marcucci, E., and Gerli, R. (2018). Targeting Inflammation to Prevent Cardiovascular Disease in Chronic Rheumatic Diseases: Myth or Reality?. Front. Cardiovasc. Med., 5.","DOI":"10.3389\/fcvm.2018.00177"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/09059180.00008014","article-title":"Rheumatoid arthritis-associated lung disease","volume":"24","author":"Shaw","year":"2015","journal-title":"Eur. Respir Rev."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Murakami, K., Kobayashi, Y., Uehara, S., Suzuki, T., Koide, M., Yamashita, T., Nakamura, M., Takahashi, N., Kato, H., and Udagawa, N. (2017). A Jak1\/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0181126"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1177\/1060028019839650","article-title":"Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis","volume":"53","author":"Mogul","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/psp4.12251","article-title":"Dose\/Exposure-Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis","volume":"6","author":"Zhang","year":"2017","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2147\/CEOR.S201621","article-title":"Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain","volume":"11","author":"Schlueter","year":"2019","journal-title":"Clin. Outcomes Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: A double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/jcph.354","article-title":"The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1\/2 inhibitor, in healthy volunteers","volume":"54","author":"Shi","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/cts.12486","article-title":"Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib","volume":"10","author":"Posada","year":"2017","journal-title":"Clin. Transl. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Payne, C., Zhang, X., Shahri, N., Williams, W., and Cannady, E. (2015). AB0492 Evaluation of Potential Drug-Drug Interactions with Baricitinib. Ann. Rheum. Dis., 74.","DOI":"10.1136\/annrheumdis-2015-eular.1627"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1042\/CS20140554","article-title":"Type I IFNs as biomarkers in rheumatoid arthritis: Towards disease profiling and personalized medicine","volume":"128","author":"Lopez","year":"2015","journal-title":"Clin. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/annrheumdis-2018-213271","article-title":"Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: Results of a prospective study","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/14397595.2017.1392057","article-title":"Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials","volume":"28","author":"Tanaka","year":"2018","journal-title":"Mod. Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Qiu, C., Zhao, X., She, L., Shi, Z., Deng, Z., Tan, L., Tu, X., Jiang, S., and Tang, B. (2019). Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: A meta-analysis of randomized controlled trials. Lipids Health Dis., 18.","DOI":"10.1186\/s12944-019-0994-7"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3899\/jrheum.171361","article-title":"Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment","volume":"46","author":"Smolen","year":"2019","journal-title":"J. Rheumatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/cpt.936","article-title":"Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients","volume":"104","author":"Kim","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Adam, S., Simon, N., Steffen, U., Andes, F., M\u00fcller, D., Culemann, S., Andreev, D., Hahn, M., Scholtysek, C., and Schett, G. (2019). P148 JAK-inhibition by baricitinib and tofacitinib ameliorates pathological bone loss. Ann. Rheum. Dis., 78.","DOI":"10.1136\/annrheumdis-2018-EWRR2019.131"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1080\/14656566.2017.1359256","article-title":"Efficacy of baricitinib in the treatment of rheumatoid arthritis","volume":"18","author":"Richez","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3797\/scipharm.1510-08","article-title":"Simultaneous Quantification of Baricitinib and Methotrexate in Rat Plasma by LC-MS\/MS: Application to a Pharmacokinetic Study","volume":"84","author":"Veeraraghavan","year":"2016","journal-title":"Sci. Pharm."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Koller, D., Vaitsekhovich, V., Mba, C., Steegmann, J.L., Zubiaur, P., Abad-Santos, F., and Wojnicz, A. (2020). Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS\/MS method with potent phospholipids clean-up procedure. Application to therapeutic drug monitoring. Talanta, 208.","DOI":"10.1016\/j.talanta.2019.120450"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/jssc.200700624","article-title":"Impact of column temperature and mobile phase components on selectivity of hydrophilic interaction chromatography (HILIC)","volume":"31","author":"Hao","year":"2008","journal-title":"J. Sep. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.5740\/jaoacint.SGE_Noga","article-title":"Hydrophilic interaction liquid chromatography and per aqueous liquid chromatography in fungicides analysis","volume":"95","author":"Buszewski","year":"2012","journal-title":"J. AOAC Int."},{"key":"ref_26","unstructured":"European Medicines Agency (2020, February 03). Olumiant, INN-Baricitinib, Summary of Product, Characteristics, 1\u201330, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/olumiant-epar-product-information_en.pdf."},{"key":"ref_27","first-page":"413","article-title":"17\u2014LC\/MS Application in High-Throughput ADME Screen","volume":"Volume 6","author":"Ahuja","year":"2005","journal-title":"Separation Science and Technology"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Wells, D.A. (2013). Bioanalytical Applications: Solid-Phase Extraction. Reference Module in Chemistry, Molecular Sciences and Chemical Engineering, Elsevier.","DOI":"10.1016\/B978-0-12-409547-2.04661-8"},{"key":"ref_29","unstructured":"(2020, February 02). Guidance for Industry on Bioanalytical Method Validation, Available online: https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf."},{"key":"ref_30","unstructured":"European Medicines Agency (2020, February 05). Guideline on Bioanalytical Method Validation, Available online: https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/7\/1600\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:13:50Z","timestamp":1760174030000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/7\/1600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,31]]},"references-count":30,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,4]]}},"alternative-id":["molecules25071600"],"URL":"https:\/\/doi.org\/10.3390\/molecules25071600","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,31]]}}}